Vimarsana
Biggest News Aggregation in the World

Robert Sidbury News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Robert Sidbury. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Robert Sidbury Today - Breaking & Trending Today

Top Tools for Measuring AD in Clinical Practice Recommended - Vimarsana News

Top Tools for Measuring AD in Clinical Practice Recommended

Consensus was reached during an in-person meeting attended by 34 individuals with diverse backgrounds.

Dr Robert Sidbury on Implementing Value-Based Care Intiatives in a Pediatric Dermatology Practice - Vimarsana News

Dr Robert Sidbury on Implementing Value-Based Care Intiatives in a Pediatric Dermatology Practice

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.

Source: ajmc.com
Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful - Vimarsana News

Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses what makes a dermatology practice successful and the challenges that come with running a practice.

Source: ajmc.com
AAD Updates Guidelines for Managing AD - Vimarsana News

AAD Updates Guidelines for Managing AD

The guidelines cover approved and off-label uses of systemic therapies and phototherapy, including new treatments that have become available since the last guidelines were published in 2014.

Dupilumab-Associated Lymphoid Reactions Require Caution - Vimarsana News

Dupilumab-Associated Lymphoid Reactions Require Caution

Retrospective study identifies potential for misdiagnosed mycosis fungoides and for dupilumab to fuel cutaneous lymphoid reactions that mimic mycosis fungoides in patients with atopic dermatitis.